Deutsche Bank has upgraded Kingfisher PLC from 'sell' to 'hold' and increased its price target to 300p from 260p. The upgrade follows better-than-expected earnings and a sequential improvement in industry data, despite ongoing UK cost pressures and a soft European consumer outlook. Deutsche Bank raised its full-year pre-tax profit forecast to £605 million, above market consensus and Kingfisher's own guidance midpoint. The bank's more neutral stance reflects confidence in Kingfisher's performance amid macroeconomic challenges.
Kingfisher's recent upgrade by Deutsche Bank is presented here alongside Pluang's Consumer Cyclical sector data for context. For readers following this sector, as of Sep 17, 2026 23:41 WIB, 70 out of 105 US stocks rose. Notably, Best Buy Co Inc increased by 3.90% to USD 95.06 with a typical hold time of 64 days and a Pluang order activity skewed 100% to sell, contrasting with Burlington Stores Inc and General Motors Company, which both rose around 3.8% and 3.6% respectively, with 100% buy order activity and shorter to longer hold times.
KB Home is set to report its Q3 2026 earnings on September 22, with analysts projecting a 45.3% drop in earnings per share to around $0.89 and a 20.2% decline in revenue to about $1.30 billion compared to last year. The consensus EPS estimate has rec...
An investment of $10,000 in Nebius when it resumed trading in 2024 has grown significantly to approximately $105,000 by 2026. This remarkable increase highlights Nebius's strong market performance over the two-year period. Investors who bought in at ...
W.P. Carey expects to invest over $1.9 billion in 2026, reflecting robust growth in its net lease property portfolio. Despite a slight reduction in its price target by Scotiabank to $76, the stock still shows potential upside from current levels. The...
Micron Technology is investing $10 billion over the next decade to establish Micron Research Labs, a new division focused on future memory architectures and advanced semiconductor manufacturing. The company shows strong financial health with a low de...
Impact Biomedical Inc. will conduct a 1-for-12.62 reverse stock split on September 23, 2026, consolidating shares without changing shareholder value. This move facilitates its planned merger with Zoar Ltd., with a Form F-4 registration filed with the...
